Global Antiretroviral Agent Market Research Report 2023
The clinical use of antiretroviral agents involves a pathogenesis-based, combination treatment approach. Increase in the number of chronic diseases, HIV infections will lead to more medicinal development. The surge for anti-resistant medicines has been in demand. In addition as monoclonal antibodies demand increases, the growth for the antiretroviral (ARV) agents market will spike its rate, demand in personalized medicines has increased bio production, accelerating antiretroviral (ARV) demand.
According to QYResearch’s new survey, global Antiretroviral Agent market is projected to reach US$ 61340 million in 2029, increasing from US$ 48350 million in 2022, with the CAGR of 3.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Antiretroviral Agent market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Antiretroviral Agent market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
According to QYResearch’s new survey, global Antiretroviral Agent market is projected to reach US$ 61340 million in 2029, increasing from US$ 48350 million in 2022, with the CAGR of 3.5% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Antiretroviral Agent market research.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Antiretroviral Agent market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
- ViiV Healthcare
- Gilead Sciences
- GlaxoSmithKline
- Merck Sharp and Dohme
- Bristol-Myers Squibb
- Janssen Pharmaceuticals
- Pfizer
- Boehringer Ingelheim
- AbbVie
- Genentech
- Mylan
- Nucleoside Reverse Transcriptase Inhibitors
- Protease Inhibitors
- HIV Integrase Strand Transfer Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Entry Inhibitors—CCR5 Co-Receptor Antagonist
- Fusion Inhibitors
- Others
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
- North America
- United States
- Canada
- Europe
- Germany
- France
- U.K.
- Italy
- Russia
- Asia-Pacific
- China
- Japan
- South Korea
- India
- Australia
- China Taiwan
- Indonesia
- Thailand
- Malaysia
- Latin America
- Mexico
- Brazil
- Argentina
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
1 ANTIRETROVIRAL AGENT MARKET OVERVIEW
1.1 Product Overview and Scope of Antiretroviral Agent
1.2 Antiretroviral Agent Segment by Type
1.2.1 Global Antiretroviral Agent Market Value Comparison by Type (2023-2029)
1.2.2 Nucleoside Reverse Transcriptase Inhibitors
1.2.3 Protease Inhibitors
1.2.4 HIV Integrase Strand Transfer Inhibitors
1.2.5 Non-Nucleoside Reverse Transcriptase Inhibitors
1.2.6 Entry Inhibitors—CCR5 Co-Receptor Antagonist
1.2.7 Fusion Inhibitors
1.2.8 Others
1.3 Antiretroviral Agent Segment by Application
1.3.1 Global Antiretroviral Agent Market Value by Application: (2023-2029)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Global Antiretroviral Agent Market Size Estimates and Forecasts
1.4.1 Global Antiretroviral Agent Revenue 2018-2029
1.4.2 Global Antiretroviral Agent Sales 2018-2029
1.4.3 Global Antiretroviral Agent Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 ANTIRETROVIRAL AGENT MARKET COMPETITION BY MANUFACTURERS
2.1 Global Antiretroviral Agent Sales Market Share by Manufacturers (2018-2023)
2.2 Global Antiretroviral Agent Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Antiretroviral Agent Average Price by Manufacturers (2018-2023)
2.4 Global Antiretroviral Agent Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Antiretroviral Agent, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antiretroviral Agent, Product Type & Application
2.7 Antiretroviral Agent Market Competitive Situation and Trends
2.7.1 Antiretroviral Agent Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antiretroviral Agent Players Market Share by Revenue
2.7.3 Global Antiretroviral Agent Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 ANTIRETROVIRAL AGENT RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global Antiretroviral Agent Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Antiretroviral Agent Global Antiretroviral Agent Sales by Region: 2018-2029
3.2.1 Global Antiretroviral Agent Sales by Region: 2018-2023
3.2.2 Global Antiretroviral Agent Sales by Region: 2024-2029
3.3 Global Antiretroviral Agent Global Antiretroviral Agent Revenue by Region: 2018-2029
3.3.1 Global Antiretroviral Agent Revenue by Region: 2018-2023
3.3.2 Global Antiretroviral Agent Revenue by Region: 2024-2029
3.4 North America Antiretroviral Agent Market Facts & Figures by Country
3.4.1 North America Antiretroviral Agent Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Antiretroviral Agent Sales by Country (2018-2029)
3.4.3 North America Antiretroviral Agent Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antiretroviral Agent Market Facts & Figures by Country
3.5.1 Europe Antiretroviral Agent Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Antiretroviral Agent Sales by Country (2018-2029)
3.5.3 Europe Antiretroviral Agent Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antiretroviral Agent Market Facts & Figures by Country
3.6.1 Asia Pacific Antiretroviral Agent Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Antiretroviral Agent Sales by Country (2018-2029)
3.6.3 Asia Pacific Antiretroviral Agent Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Antiretroviral Agent Market Facts & Figures by Country
3.7.1 Latin America Antiretroviral Agent Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Antiretroviral Agent Sales by Country (2018-2029)
3.7.3 Latin America Antiretroviral Agent Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antiretroviral Agent Market Facts & Figures by Country
3.8.1 Middle East and Africa Antiretroviral Agent Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Antiretroviral Agent Sales by Country (2018-2029)
3.8.3 Middle East and Africa Antiretroviral Agent Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 SEGMENT BY TYPE
4.1 Global Antiretroviral Agent Sales by Type (2018-2029)
4.1.1 Global Antiretroviral Agent Sales by Type (2018-2023)
4.1.2 Global Antiretroviral Agent Sales by Type (2024-2029)
4.1.3 Global Antiretroviral Agent Sales Market Share by Type (2018-2029)
4.2 Global Antiretroviral Agent Revenue by Type (2018-2029)
4.2.1 Global Antiretroviral Agent Revenue by Type (2018-2023)
4.2.2 Global Antiretroviral Agent Revenue by Type (2024-2029)
4.2.3 Global Antiretroviral Agent Revenue Market Share by Type (2018-2029)
4.3 Global Antiretroviral Agent Price by Type (2018-2029)
5 SEGMENT BY APPLICATION
5.1 Global Antiretroviral Agent Sales by Application (2018-2029)
5.1.1 Global Antiretroviral Agent Sales by Application (2018-2023)
5.1.2 Global Antiretroviral Agent Sales by Application (2024-2029)
5.1.3 Global Antiretroviral Agent Sales Market Share by Application (2018-2029)
5.2 Global Antiretroviral Agent Revenue by Application (2018-2029)
5.2.1 Global Antiretroviral Agent Revenue by Application (2018-2023)
5.2.2 Global Antiretroviral Agent Revenue by Application (2024-2029)
5.2.3 Global Antiretroviral Agent Revenue Market Share by Application (2018-2029)
5.3 Global Antiretroviral Agent Price by Application (2018-2029)
6 KEY COMPANIES PROFILED
6.1 ViiV Healthcare
6.1.1 ViiV Healthcare Corporation Information
6.1.2 ViiV Healthcare Description and Business Overview
6.1.3 ViiV Healthcare Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.1.4 ViiV Healthcare Antiretroviral Agent Product Portfolio
6.1.5 ViiV Healthcare Recent Developments/Updates
6.2 Gilead Sciences
6.2.1 Gilead Sciences Corporation Information
6.2.2 Gilead Sciences Description and Business Overview
6.2.3 Gilead Sciences Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Gilead Sciences Antiretroviral Agent Product Portfolio
6.2.5 Gilead Sciences Recent Developments/Updates
6.3 GlaxoSmithKline
6.3.1 GlaxoSmithKline Corporation Information
6.3.2 GlaxoSmithKline Description and Business Overview
6.3.3 GlaxoSmithKline Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.3.4 GlaxoSmithKline Antiretroviral Agent Product Portfolio
6.3.5 GlaxoSmithKline Recent Developments/Updates
6.4 Merck Sharp and Dohme
6.4.1 Merck Sharp and Dohme Corporation Information
6.4.2 Merck Sharp and Dohme Description and Business Overview
6.4.3 Merck Sharp and Dohme Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Merck Sharp and Dohme Antiretroviral Agent Product Portfolio
6.4.5 Merck Sharp and Dohme Recent Developments/Updates
6.5 Bristol-Myers Squibb
6.5.1 Bristol-Myers Squibb Corporation Information
6.5.2 Bristol-Myers Squibb Description and Business Overview
6.5.3 Bristol-Myers Squibb Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Bristol-Myers Squibb Antiretroviral Agent Product Portfolio
6.5.5 Bristol-Myers Squibb Recent Developments/Updates
6.6 Janssen Pharmaceuticals
6.6.1 Janssen Pharmaceuticals Corporation Information
6.6.2 Janssen Pharmaceuticals Description and Business Overview
6.6.3 Janssen Pharmaceuticals Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Janssen Pharmaceuticals Antiretroviral Agent Product Portfolio
6.6.5 Janssen Pharmaceuticals Recent Developments/Updates
6.7 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Antiretroviral Agent Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Boehringer Ingelheim
6.8.1 Boehringer Ingelheim Corporation Information
6.8.2 Boehringer Ingelheim Description and Business Overview
6.8.3 Boehringer Ingelheim Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Boehringer Ingelheim Antiretroviral Agent Product Portfolio
6.8.5 Boehringer Ingelheim Recent Developments/Updates
6.9 AbbVie
6.9.1 AbbVie Corporation Information
6.9.2 AbbVie Description and Business Overview
6.9.3 AbbVie Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.9.4 AbbVie Antiretroviral Agent Product Portfolio
6.9.5 AbbVie Recent Developments/Updates
6.10 Genentech
6.10.1 Genentech Corporation Information
6.10.2 Genentech Description and Business Overview
6.10.3 Genentech Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Genentech Antiretroviral Agent Product Portfolio
6.10.5 Genentech Recent Developments/Updates
6.11 Mylan
6.11.1 Mylan Corporation Information
6.11.2 Mylan Antiretroviral Agent Description and Business Overview
6.11.3 Mylan Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Mylan Antiretroviral Agent Product Portfolio
6.11.5 Mylan Recent Developments/Updates
7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
7.1 Antiretroviral Agent Industry Chain Analysis
7.2 Antiretroviral Agent Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antiretroviral Agent Production Mode & Process
7.4 Antiretroviral Agent Sales and Marketing
7.4.1 Antiretroviral Agent Sales Channels
7.4.2 Antiretroviral Agent Distributors
7.5 Antiretroviral Agent Customers
8 ANTIRETROVIRAL AGENT MARKET DYNAMICS
8.1 Antiretroviral Agent Industry Trends
8.2 Antiretroviral Agent Market Drivers
8.3 Antiretroviral Agent Market Challenges
8.4 Antiretroviral Agent Market Restraints
9 RESEARCH FINDING AND CONCLUSION
10 METHODOLOGY AND DATA SOURCE
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
1.1 Product Overview and Scope of Antiretroviral Agent
1.2 Antiretroviral Agent Segment by Type
1.2.1 Global Antiretroviral Agent Market Value Comparison by Type (2023-2029)
1.2.2 Nucleoside Reverse Transcriptase Inhibitors
1.2.3 Protease Inhibitors
1.2.4 HIV Integrase Strand Transfer Inhibitors
1.2.5 Non-Nucleoside Reverse Transcriptase Inhibitors
1.2.6 Entry Inhibitors—CCR5 Co-Receptor Antagonist
1.2.7 Fusion Inhibitors
1.2.8 Others
1.3 Antiretroviral Agent Segment by Application
1.3.1 Global Antiretroviral Agent Market Value by Application: (2023-2029)
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Global Antiretroviral Agent Market Size Estimates and Forecasts
1.4.1 Global Antiretroviral Agent Revenue 2018-2029
1.4.2 Global Antiretroviral Agent Sales 2018-2029
1.4.3 Global Antiretroviral Agent Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 ANTIRETROVIRAL AGENT MARKET COMPETITION BY MANUFACTURERS
2.1 Global Antiretroviral Agent Sales Market Share by Manufacturers (2018-2023)
2.2 Global Antiretroviral Agent Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Antiretroviral Agent Average Price by Manufacturers (2018-2023)
2.4 Global Antiretroviral Agent Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Antiretroviral Agent, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Antiretroviral Agent, Product Type & Application
2.7 Antiretroviral Agent Market Competitive Situation and Trends
2.7.1 Antiretroviral Agent Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Antiretroviral Agent Players Market Share by Revenue
2.7.3 Global Antiretroviral Agent Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 ANTIRETROVIRAL AGENT RETROSPECTIVE MARKET SCENARIO BY REGION
3.1 Global Antiretroviral Agent Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Antiretroviral Agent Global Antiretroviral Agent Sales by Region: 2018-2029
3.2.1 Global Antiretroviral Agent Sales by Region: 2018-2023
3.2.2 Global Antiretroviral Agent Sales by Region: 2024-2029
3.3 Global Antiretroviral Agent Global Antiretroviral Agent Revenue by Region: 2018-2029
3.3.1 Global Antiretroviral Agent Revenue by Region: 2018-2023
3.3.2 Global Antiretroviral Agent Revenue by Region: 2024-2029
3.4 North America Antiretroviral Agent Market Facts & Figures by Country
3.4.1 North America Antiretroviral Agent Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Antiretroviral Agent Sales by Country (2018-2029)
3.4.3 North America Antiretroviral Agent Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Antiretroviral Agent Market Facts & Figures by Country
3.5.1 Europe Antiretroviral Agent Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Antiretroviral Agent Sales by Country (2018-2029)
3.5.3 Europe Antiretroviral Agent Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Antiretroviral Agent Market Facts & Figures by Country
3.6.1 Asia Pacific Antiretroviral Agent Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Antiretroviral Agent Sales by Country (2018-2029)
3.6.3 Asia Pacific Antiretroviral Agent Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Antiretroviral Agent Market Facts & Figures by Country
3.7.1 Latin America Antiretroviral Agent Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Antiretroviral Agent Sales by Country (2018-2029)
3.7.3 Latin America Antiretroviral Agent Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Antiretroviral Agent Market Facts & Figures by Country
3.8.1 Middle East and Africa Antiretroviral Agent Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Antiretroviral Agent Sales by Country (2018-2029)
3.8.3 Middle East and Africa Antiretroviral Agent Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 SEGMENT BY TYPE
4.1 Global Antiretroviral Agent Sales by Type (2018-2029)
4.1.1 Global Antiretroviral Agent Sales by Type (2018-2023)
4.1.2 Global Antiretroviral Agent Sales by Type (2024-2029)
4.1.3 Global Antiretroviral Agent Sales Market Share by Type (2018-2029)
4.2 Global Antiretroviral Agent Revenue by Type (2018-2029)
4.2.1 Global Antiretroviral Agent Revenue by Type (2018-2023)
4.2.2 Global Antiretroviral Agent Revenue by Type (2024-2029)
4.2.3 Global Antiretroviral Agent Revenue Market Share by Type (2018-2029)
4.3 Global Antiretroviral Agent Price by Type (2018-2029)
5 SEGMENT BY APPLICATION
5.1 Global Antiretroviral Agent Sales by Application (2018-2029)
5.1.1 Global Antiretroviral Agent Sales by Application (2018-2023)
5.1.2 Global Antiretroviral Agent Sales by Application (2024-2029)
5.1.3 Global Antiretroviral Agent Sales Market Share by Application (2018-2029)
5.2 Global Antiretroviral Agent Revenue by Application (2018-2029)
5.2.1 Global Antiretroviral Agent Revenue by Application (2018-2023)
5.2.2 Global Antiretroviral Agent Revenue by Application (2024-2029)
5.2.3 Global Antiretroviral Agent Revenue Market Share by Application (2018-2029)
5.3 Global Antiretroviral Agent Price by Application (2018-2029)
6 KEY COMPANIES PROFILED
6.1 ViiV Healthcare
6.1.1 ViiV Healthcare Corporation Information
6.1.2 ViiV Healthcare Description and Business Overview
6.1.3 ViiV Healthcare Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.1.4 ViiV Healthcare Antiretroviral Agent Product Portfolio
6.1.5 ViiV Healthcare Recent Developments/Updates
6.2 Gilead Sciences
6.2.1 Gilead Sciences Corporation Information
6.2.2 Gilead Sciences Description and Business Overview
6.2.3 Gilead Sciences Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Gilead Sciences Antiretroviral Agent Product Portfolio
6.2.5 Gilead Sciences Recent Developments/Updates
6.3 GlaxoSmithKline
6.3.1 GlaxoSmithKline Corporation Information
6.3.2 GlaxoSmithKline Description and Business Overview
6.3.3 GlaxoSmithKline Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.3.4 GlaxoSmithKline Antiretroviral Agent Product Portfolio
6.3.5 GlaxoSmithKline Recent Developments/Updates
6.4 Merck Sharp and Dohme
6.4.1 Merck Sharp and Dohme Corporation Information
6.4.2 Merck Sharp and Dohme Description and Business Overview
6.4.3 Merck Sharp and Dohme Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Merck Sharp and Dohme Antiretroviral Agent Product Portfolio
6.4.5 Merck Sharp and Dohme Recent Developments/Updates
6.5 Bristol-Myers Squibb
6.5.1 Bristol-Myers Squibb Corporation Information
6.5.2 Bristol-Myers Squibb Description and Business Overview
6.5.3 Bristol-Myers Squibb Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Bristol-Myers Squibb Antiretroviral Agent Product Portfolio
6.5.5 Bristol-Myers Squibb Recent Developments/Updates
6.6 Janssen Pharmaceuticals
6.6.1 Janssen Pharmaceuticals Corporation Information
6.6.2 Janssen Pharmaceuticals Description and Business Overview
6.6.3 Janssen Pharmaceuticals Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Janssen Pharmaceuticals Antiretroviral Agent Product Portfolio
6.6.5 Janssen Pharmaceuticals Recent Developments/Updates
6.7 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Pfizer Antiretroviral Agent Product Portfolio
6.7.5 Pfizer Recent Developments/Updates
6.8 Boehringer Ingelheim
6.8.1 Boehringer Ingelheim Corporation Information
6.8.2 Boehringer Ingelheim Description and Business Overview
6.8.3 Boehringer Ingelheim Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Boehringer Ingelheim Antiretroviral Agent Product Portfolio
6.8.5 Boehringer Ingelheim Recent Developments/Updates
6.9 AbbVie
6.9.1 AbbVie Corporation Information
6.9.2 AbbVie Description and Business Overview
6.9.3 AbbVie Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.9.4 AbbVie Antiretroviral Agent Product Portfolio
6.9.5 AbbVie Recent Developments/Updates
6.10 Genentech
6.10.1 Genentech Corporation Information
6.10.2 Genentech Description and Business Overview
6.10.3 Genentech Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Genentech Antiretroviral Agent Product Portfolio
6.10.5 Genentech Recent Developments/Updates
6.11 Mylan
6.11.1 Mylan Corporation Information
6.11.2 Mylan Antiretroviral Agent Description and Business Overview
6.11.3 Mylan Antiretroviral Agent Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Mylan Antiretroviral Agent Product Portfolio
6.11.5 Mylan Recent Developments/Updates
7 INDUSTRY CHAIN AND SALES CHANNELS ANALYSIS
7.1 Antiretroviral Agent Industry Chain Analysis
7.2 Antiretroviral Agent Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Antiretroviral Agent Production Mode & Process
7.4 Antiretroviral Agent Sales and Marketing
7.4.1 Antiretroviral Agent Sales Channels
7.4.2 Antiretroviral Agent Distributors
7.5 Antiretroviral Agent Customers
8 ANTIRETROVIRAL AGENT MARKET DYNAMICS
8.1 Antiretroviral Agent Industry Trends
8.2 Antiretroviral Agent Market Drivers
8.3 Antiretroviral Agent Market Challenges
8.4 Antiretroviral Agent Market Restraints
9 RESEARCH FINDING AND CONCLUSION
10 METHODOLOGY AND DATA SOURCE
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
LIST OF TABLES
Table 1. Global Antiretroviral Agent Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Antiretroviral Agent Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Antiretroviral Agent Market Competitive Situation by Manufacturers in 2022
Table 4. Global Antiretroviral Agent Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Antiretroviral Agent Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Antiretroviral Agent Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Antiretroviral Agent Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Antiretroviral Agent Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Antiretroviral Agent, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Antiretroviral Agent, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Antiretroviral Agent, Product Type & Application
Table 12. Global Key Manufacturers of Antiretroviral Agent, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Antiretroviral Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antiretroviral Agent as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Antiretroviral Agent Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Antiretroviral Agent Sales by Region (2018-2023) & (K Units)
Table 18. Global Antiretroviral Agent Sales Market Share by Region (2018-2023)
Table 19. Global Antiretroviral Agent Sales by Region (2024-2029) & (K Units)
Table 20. Global Antiretroviral Agent Sales Market Share by Region (2024-2029)
Table 21. Global Antiretroviral Agent Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Antiretroviral Agent Revenue Market Share by Region (2018-2023)
Table 23. Global Antiretroviral Agent Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Antiretroviral Agent Revenue Market Share by Region (2024-2029)
Table 25. North America Antiretroviral Agent Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Antiretroviral Agent Sales by Country (2018-2023) & (K Units)
Table 27. North America Antiretroviral Agent Sales by Country (2024-2029) & (K Units)
Table 28. North America Antiretroviral Agent Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Antiretroviral Agent Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Antiretroviral Agent Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Antiretroviral Agent Sales by Country (2018-2023) & (K Units)
Table 32. Europe Antiretroviral Agent Sales by Country (2024-2029) & (K Units)
Table 33. Europe Antiretroviral Agent Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Antiretroviral Agent Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Antiretroviral Agent Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Antiretroviral Agent Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Antiretroviral Agent Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Antiretroviral Agent Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Antiretroviral Agent Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Antiretroviral Agent Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Antiretroviral Agent Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Antiretroviral Agent Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Antiretroviral Agent Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Antiretroviral Agent Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Antiretroviral Agent Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Antiretroviral Agent Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Antiretroviral Agent Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Antiretroviral Agent Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Antiretroviral Agent Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Antiretroviral Agent Sales (K Units) by Type (2018-2023)
Table 51. Global Antiretroviral Agent Sales (K Units) by Type (2024-2029)
Table 52. Global Antiretroviral Agent Sales Market Share by Type (2018-2023)
Table 53. Global Antiretroviral Agent Sales Market Share by Type (2024-2029)
Table 54. Global Antiretroviral Agent Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Antiretroviral Agent Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Antiretroviral Agent Revenue Market Share by Type (2018-2023)
Table 57. Global Antiretroviral Agent Revenue Market Share by Type (2024-2029)
Table 58. Global Antiretroviral Agent Price (US$/Unit) by Type (2018-2023)
Table 59. Global Antiretroviral Agent Price (US$/Unit) by Type (2024-2029)
Table 60. Global Antiretroviral Agent Sales (K Units) by Application (2018-2023)
Table 61. Global Antiretroviral Agent Sales (K Units) by Application (2024-2029)
Table 62. Global Antiretroviral Agent Sales Market Share by Application (2018-2023)
Table 63. Global Antiretroviral Agent Sales Market Share by Application (2024-2029)
Table 64. Global Antiretroviral Agent Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Antiretroviral Agent Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Antiretroviral Agent Revenue Market Share by Application (2018-2023)
Table 67. Global Antiretroviral Agent Revenue Market Share by Application (2024-2029)
Table 68. Global Antiretroviral Agent Price (US$/Unit) by Application (2018-2023)
Table 69. Global Antiretroviral Agent Price (US$/Unit) by Application (2024-2029)
Table 70. ViiV Healthcare Corporation Information
Table 71. ViiV Healthcare Description and Business Overview
Table 72. ViiV Healthcare Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. ViiV Healthcare Antiretroviral Agent Product
Table 74. ViiV Healthcare Recent Developments/Updates
Table 75. Gilead Sciences Corporation Information
Table 76. Gilead Sciences Description and Business Overview
Table 77. Gilead Sciences Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Gilead Sciences Antiretroviral Agent Product
Table 79. Gilead Sciences Recent Developments/Updates
Table 80. GlaxoSmithKline Corporation Information
Table 81. GlaxoSmithKline Description and Business Overview
Table 82. GlaxoSmithKline Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. GlaxoSmithKline Antiretroviral Agent Product
Table 84. GlaxoSmithKline Recent Developments/Updates
Table 85. Merck Sharp and Dohme Corporation Information
Table 86. Merck Sharp and Dohme Description and Business Overview
Table 87. Merck Sharp and Dohme Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Merck Sharp and Dohme Antiretroviral Agent Product
Table 89. Merck Sharp and Dohme Recent Developments/Updates
Table 90. Bristol-Myers Squibb Corporation Information
Table 91. Bristol-Myers Squibb Description and Business Overview
Table 92. Bristol-Myers Squibb Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Bristol-Myers Squibb Antiretroviral Agent Product
Table 94. Bristol-Myers Squibb Recent Developments/Updates
Table 95. Janssen Pharmaceuticals Corporation Information
Table 96. Janssen Pharmaceuticals Description and Business Overview
Table 97. Janssen Pharmaceuticals Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Janssen Pharmaceuticals Antiretroviral Agent Product
Table 99. Janssen Pharmaceuticals Recent Developments/Updates
Table 100. Pfizer Corporation Information
Table 101. Pfizer Description and Business Overview
Table 102. Pfizer Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Pfizer Antiretroviral Agent Product
Table 104. Pfizer Recent Developments/Updates
Table 105. Boehringer Ingelheim Corporation Information
Table 106. Boehringer Ingelheim Description and Business Overview
Table 107. Boehringer Ingelheim Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Boehringer Ingelheim Antiretroviral Agent Product
Table 109. Boehringer Ingelheim Recent Developments/Updates
Table 110. AbbVie Corporation Information
Table 111. AbbVie Description and Business Overview
Table 112. AbbVie Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. AbbVie Antiretroviral Agent Product
Table 114. AbbVie Recent Developments/Updates
Table 115. Genentech Corporation Information
Table 116. Genentech Description and Business Overview
Table 117. Genentech Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Genentech Antiretroviral Agent Product
Table 119. Genentech Recent Developments/Updates
Table 120. Mylan Corporation Information
Table 121. Mylan Description and Business Overview
Table 122. Mylan Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Mylan Antiretroviral Agent Product
Table 124. Mylan Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Antiretroviral Agent Distributors List
Table 128. Antiretroviral Agent Customers List
Table 129. Antiretroviral Agent Market Trends
Table 130. Antiretroviral Agent Market Drivers
Table 131. Antiretroviral Agent Market Challenges
Table 132. Antiretroviral Agent Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
Table 1. Global Antiretroviral Agent Market Value Comparison by Type (2023-2029) & (US$ Million)
Table 2. Global Antiretroviral Agent Market Value Comparison by Application (2023-2029) & (US$ Million)
Table 3. Global Antiretroviral Agent Market Competitive Situation by Manufacturers in 2022
Table 4. Global Antiretroviral Agent Sales (K Units) of Key Manufacturers (2018-2023)
Table 5. Global Antiretroviral Agent Sales Market Share by Manufacturers (2018-2023)
Table 6. Global Antiretroviral Agent Revenue (US$ Million) by Manufacturers (2018-2023)
Table 7. Global Antiretroviral Agent Revenue Share by Manufacturers (2018-2023)
Table 8. Global Market Antiretroviral Agent Average Price (US$/Unit) of Key Manufacturers (2018-2023)
Table 9. Global Key Players of Antiretroviral Agent, Industry Ranking, 2021 VS 2022 VS 2023
Table 10. Global Key Manufacturers of Antiretroviral Agent, Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Antiretroviral Agent, Product Type & Application
Table 12. Global Key Manufacturers of Antiretroviral Agent, Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Antiretroviral Agent by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antiretroviral Agent as of 2022)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Antiretroviral Agent Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 17. Global Antiretroviral Agent Sales by Region (2018-2023) & (K Units)
Table 18. Global Antiretroviral Agent Sales Market Share by Region (2018-2023)
Table 19. Global Antiretroviral Agent Sales by Region (2024-2029) & (K Units)
Table 20. Global Antiretroviral Agent Sales Market Share by Region (2024-2029)
Table 21. Global Antiretroviral Agent Revenue by Region (2018-2023) & (US$ Million)
Table 22. Global Antiretroviral Agent Revenue Market Share by Region (2018-2023)
Table 23. Global Antiretroviral Agent Revenue by Region (2024-2029) & (US$ Million)
Table 24. Global Antiretroviral Agent Revenue Market Share by Region (2024-2029)
Table 25. North America Antiretroviral Agent Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 26. North America Antiretroviral Agent Sales by Country (2018-2023) & (K Units)
Table 27. North America Antiretroviral Agent Sales by Country (2024-2029) & (K Units)
Table 28. North America Antiretroviral Agent Revenue by Country (2018-2023) & (US$ Million)
Table 29. North America Antiretroviral Agent Revenue by Country (2024-2029) & (US$ Million)
Table 30. Europe Antiretroviral Agent Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 31. Europe Antiretroviral Agent Sales by Country (2018-2023) & (K Units)
Table 32. Europe Antiretroviral Agent Sales by Country (2024-2029) & (K Units)
Table 33. Europe Antiretroviral Agent Revenue by Country (2018-2023) & (US$ Million)
Table 34. Europe Antiretroviral Agent Revenue by Country (2024-2029) & (US$ Million)
Table 35. Asia Pacific Antiretroviral Agent Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 36. Asia Pacific Antiretroviral Agent Sales by Region (2018-2023) & (K Units)
Table 37. Asia Pacific Antiretroviral Agent Sales by Region (2024-2029) & (K Units)
Table 38. Asia Pacific Antiretroviral Agent Revenue by Region (2018-2023) & (US$ Million)
Table 39. Asia Pacific Antiretroviral Agent Revenue by Region (2024-2029) & (US$ Million)
Table 40. Latin America Antiretroviral Agent Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 41. Latin America Antiretroviral Agent Sales by Country (2018-2023) & (K Units)
Table 42. Latin America Antiretroviral Agent Sales by Country (2024-2029) & (K Units)
Table 43. Latin America Antiretroviral Agent Revenue by Country (2018-2023) & (US$ Million)
Table 44. Latin America Antiretroviral Agent Revenue by Country (2024-2029) & (US$ Million)
Table 45. Middle East & Africa Antiretroviral Agent Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 46. Middle East & Africa Antiretroviral Agent Sales by Country (2018-2023) & (K Units)
Table 47. Middle East & Africa Antiretroviral Agent Sales by Country (2024-2029) & (K Units)
Table 48. Middle East & Africa Antiretroviral Agent Revenue by Country (2018-2023) & (US$ Million)
Table 49. Middle East & Africa Antiretroviral Agent Revenue by Country (2024-2029) & (US$ Million)
Table 50. Global Antiretroviral Agent Sales (K Units) by Type (2018-2023)
Table 51. Global Antiretroviral Agent Sales (K Units) by Type (2024-2029)
Table 52. Global Antiretroviral Agent Sales Market Share by Type (2018-2023)
Table 53. Global Antiretroviral Agent Sales Market Share by Type (2024-2029)
Table 54. Global Antiretroviral Agent Revenue (US$ Million) by Type (2018-2023)
Table 55. Global Antiretroviral Agent Revenue (US$ Million) by Type (2024-2029)
Table 56. Global Antiretroviral Agent Revenue Market Share by Type (2018-2023)
Table 57. Global Antiretroviral Agent Revenue Market Share by Type (2024-2029)
Table 58. Global Antiretroviral Agent Price (US$/Unit) by Type (2018-2023)
Table 59. Global Antiretroviral Agent Price (US$/Unit) by Type (2024-2029)
Table 60. Global Antiretroviral Agent Sales (K Units) by Application (2018-2023)
Table 61. Global Antiretroviral Agent Sales (K Units) by Application (2024-2029)
Table 62. Global Antiretroviral Agent Sales Market Share by Application (2018-2023)
Table 63. Global Antiretroviral Agent Sales Market Share by Application (2024-2029)
Table 64. Global Antiretroviral Agent Revenue (US$ Million) by Application (2018-2023)
Table 65. Global Antiretroviral Agent Revenue (US$ Million) by Application (2024-2029)
Table 66. Global Antiretroviral Agent Revenue Market Share by Application (2018-2023)
Table 67. Global Antiretroviral Agent Revenue Market Share by Application (2024-2029)
Table 68. Global Antiretroviral Agent Price (US$/Unit) by Application (2018-2023)
Table 69. Global Antiretroviral Agent Price (US$/Unit) by Application (2024-2029)
Table 70. ViiV Healthcare Corporation Information
Table 71. ViiV Healthcare Description and Business Overview
Table 72. ViiV Healthcare Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 73. ViiV Healthcare Antiretroviral Agent Product
Table 74. ViiV Healthcare Recent Developments/Updates
Table 75. Gilead Sciences Corporation Information
Table 76. Gilead Sciences Description and Business Overview
Table 77. Gilead Sciences Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 78. Gilead Sciences Antiretroviral Agent Product
Table 79. Gilead Sciences Recent Developments/Updates
Table 80. GlaxoSmithKline Corporation Information
Table 81. GlaxoSmithKline Description and Business Overview
Table 82. GlaxoSmithKline Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 83. GlaxoSmithKline Antiretroviral Agent Product
Table 84. GlaxoSmithKline Recent Developments/Updates
Table 85. Merck Sharp and Dohme Corporation Information
Table 86. Merck Sharp and Dohme Description and Business Overview
Table 87. Merck Sharp and Dohme Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 88. Merck Sharp and Dohme Antiretroviral Agent Product
Table 89. Merck Sharp and Dohme Recent Developments/Updates
Table 90. Bristol-Myers Squibb Corporation Information
Table 91. Bristol-Myers Squibb Description and Business Overview
Table 92. Bristol-Myers Squibb Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 93. Bristol-Myers Squibb Antiretroviral Agent Product
Table 94. Bristol-Myers Squibb Recent Developments/Updates
Table 95. Janssen Pharmaceuticals Corporation Information
Table 96. Janssen Pharmaceuticals Description and Business Overview
Table 97. Janssen Pharmaceuticals Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 98. Janssen Pharmaceuticals Antiretroviral Agent Product
Table 99. Janssen Pharmaceuticals Recent Developments/Updates
Table 100. Pfizer Corporation Information
Table 101. Pfizer Description and Business Overview
Table 102. Pfizer Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 103. Pfizer Antiretroviral Agent Product
Table 104. Pfizer Recent Developments/Updates
Table 105. Boehringer Ingelheim Corporation Information
Table 106. Boehringer Ingelheim Description and Business Overview
Table 107. Boehringer Ingelheim Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 108. Boehringer Ingelheim Antiretroviral Agent Product
Table 109. Boehringer Ingelheim Recent Developments/Updates
Table 110. AbbVie Corporation Information
Table 111. AbbVie Description and Business Overview
Table 112. AbbVie Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 113. AbbVie Antiretroviral Agent Product
Table 114. AbbVie Recent Developments/Updates
Table 115. Genentech Corporation Information
Table 116. Genentech Description and Business Overview
Table 117. Genentech Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 118. Genentech Antiretroviral Agent Product
Table 119. Genentech Recent Developments/Updates
Table 120. Mylan Corporation Information
Table 121. Mylan Description and Business Overview
Table 122. Mylan Antiretroviral Agent Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 123. Mylan Antiretroviral Agent Product
Table 124. Mylan Recent Developments/Updates
Table 125. Key Raw Materials Lists
Table 126. Raw Materials Key Suppliers Lists
Table 127. Antiretroviral Agent Distributors List
Table 128. Antiretroviral Agent Customers List
Table 129. Antiretroviral Agent Market Trends
Table 130. Antiretroviral Agent Market Drivers
Table 131. Antiretroviral Agent Market Challenges
Table 132. Antiretroviral Agent Market Restraints
Table 133. Research Programs/Design for This Report
Table 134. Key Data Information from Secondary Sources
Table 135. Key Data Information from Primary Sources
LIST OF FIGURES
Figure 1. Product Picture of Antiretroviral Agent
Figure 2. Global Antiretroviral Agent Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Antiretroviral Agent Market Share by Type in 2022 & 2029
Figure 4. Nucleoside Reverse Transcriptase Inhibitors Product Picture
Figure 5. Protease Inhibitors Product Picture
Figure 6. HIV Integrase Strand Transfer Inhibitors Product Picture
Figure 7. Non-Nucleoside Reverse Transcriptase Inhibitors Product Picture
Figure 8. Entry Inhibitors—CCR5 Co-Receptor Antagonist Product Picture
Figure 9. Fusion Inhibitors Product Picture
Figure 10. Others Product Picture
Figure 11. Global Antiretroviral Agent Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 12. Global Antiretroviral Agent Market Share by Application in 2022 & 2029
Figure 13. Hospital Pharmacies
Figure 14. Retail Pharmacies
Figure 15. Online Pharmacies
Figure 16. Others
Figure 17. Global Antiretroviral Agent Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 18. Global Antiretroviral Agent Market Size (2018-2029) & (US$ Million)
Figure 19. Global Antiretroviral Agent Sales (2018-2029) & (K Units)
Figure 20. Global Antiretroviral Agent Average Price (US$/Unit) & (2018-2029)
Figure 21. Antiretroviral Agent Report Years Considered
Figure 22. Antiretroviral Agent Sales Share by Manufacturers in 2022
Figure 23. Global Antiretroviral Agent Revenue Share by Manufacturers in 2022
Figure 24. The Global 5 and 10 Largest Antiretroviral Agent Players: Market Share by Revenue in 2022
Figure 25. Antiretroviral Agent Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 26. Global Antiretroviral Agent Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 27. North America Antiretroviral Agent Sales Market Share by Country (2018-2029)
Figure 28. North America Antiretroviral Agent Revenue Market Share by Country (2018-2029)
Figure 29. United States Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Canada Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Europe Antiretroviral Agent Sales Market Share by Country (2018-2029)
Figure 32. Europe Antiretroviral Agent Revenue Market Share by Country (2018-2029)
Figure 33. Germany Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. France Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. U.K. Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Italy Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Russia Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Asia Pacific Antiretroviral Agent Sales Market Share by Region (2018-2029)
Figure 39. Asia Pacific Antiretroviral Agent Revenue Market Share by Region (2018-2029)
Figure 40. China Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Japan Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. South Korea Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. India Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Australia Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. China Taiwan Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Indonesia Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Thailand Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Malaysia Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Latin America Antiretroviral Agent Sales Market Share by Country (2018-2029)
Figure 50. Latin America Antiretroviral Agent Revenue Market Share by Country (2018-2029)
Figure 51. Mexico Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Brazil Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Argentina Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Middle East & Africa Antiretroviral Agent Sales Market Share by Country (2018-2029)
Figure 55. Middle East & Africa Antiretroviral Agent Revenue Market Share by Country (2018-2029)
Figure 56. Turkey Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 57. Saudi Arabia Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 58. UAE Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 59. Global Sales Market Share of Antiretroviral Agent by Type (2018-2029)
Figure 60. Global Revenue Market Share of Antiretroviral Agent by Type (2018-2029)
Figure 61. Global Antiretroviral Agent Price (US$/Unit) by Type (2018-2029)
Figure 62. Global Sales Market Share of Antiretroviral Agent by Application (2018-2029)
Figure 63. Global Revenue Market Share of Antiretroviral Agent by Application (2018-2029)
Figure 64. Global Antiretroviral Agent Price (US$/Unit) by Application (2018-2029)
Figure 65. Antiretroviral Agent Value Chain
Figure 66. Antiretroviral Agent Production Process
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Distributors Profiles
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
Figure 1. Product Picture of Antiretroviral Agent
Figure 2. Global Antiretroviral Agent Market Value Comparison by Type (2023-2029) & (US$ Million)
Figure 3. Global Antiretroviral Agent Market Share by Type in 2022 & 2029
Figure 4. Nucleoside Reverse Transcriptase Inhibitors Product Picture
Figure 5. Protease Inhibitors Product Picture
Figure 6. HIV Integrase Strand Transfer Inhibitors Product Picture
Figure 7. Non-Nucleoside Reverse Transcriptase Inhibitors Product Picture
Figure 8. Entry Inhibitors—CCR5 Co-Receptor Antagonist Product Picture
Figure 9. Fusion Inhibitors Product Picture
Figure 10. Others Product Picture
Figure 11. Global Antiretroviral Agent Market Value Comparison by Application (2023-2029) & (US$ Million)
Figure 12. Global Antiretroviral Agent Market Share by Application in 2022 & 2029
Figure 13. Hospital Pharmacies
Figure 14. Retail Pharmacies
Figure 15. Online Pharmacies
Figure 16. Others
Figure 17. Global Antiretroviral Agent Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 18. Global Antiretroviral Agent Market Size (2018-2029) & (US$ Million)
Figure 19. Global Antiretroviral Agent Sales (2018-2029) & (K Units)
Figure 20. Global Antiretroviral Agent Average Price (US$/Unit) & (2018-2029)
Figure 21. Antiretroviral Agent Report Years Considered
Figure 22. Antiretroviral Agent Sales Share by Manufacturers in 2022
Figure 23. Global Antiretroviral Agent Revenue Share by Manufacturers in 2022
Figure 24. The Global 5 and 10 Largest Antiretroviral Agent Players: Market Share by Revenue in 2022
Figure 25. Antiretroviral Agent Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022
Figure 26. Global Antiretroviral Agent Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Figure 27. North America Antiretroviral Agent Sales Market Share by Country (2018-2029)
Figure 28. North America Antiretroviral Agent Revenue Market Share by Country (2018-2029)
Figure 29. United States Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 30. Canada Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 31. Europe Antiretroviral Agent Sales Market Share by Country (2018-2029)
Figure 32. Europe Antiretroviral Agent Revenue Market Share by Country (2018-2029)
Figure 33. Germany Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 34. France Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 35. U.K. Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 36. Italy Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 37. Russia Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 38. Asia Pacific Antiretroviral Agent Sales Market Share by Region (2018-2029)
Figure 39. Asia Pacific Antiretroviral Agent Revenue Market Share by Region (2018-2029)
Figure 40. China Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 41. Japan Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 42. South Korea Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 43. India Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 44. Australia Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 45. China Taiwan Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 46. Indonesia Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 47. Thailand Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 48. Malaysia Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 49. Latin America Antiretroviral Agent Sales Market Share by Country (2018-2029)
Figure 50. Latin America Antiretroviral Agent Revenue Market Share by Country (2018-2029)
Figure 51. Mexico Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 52. Brazil Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 53. Argentina Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 54. Middle East & Africa Antiretroviral Agent Sales Market Share by Country (2018-2029)
Figure 55. Middle East & Africa Antiretroviral Agent Revenue Market Share by Country (2018-2029)
Figure 56. Turkey Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 57. Saudi Arabia Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 58. UAE Antiretroviral Agent Revenue Growth Rate (2018-2029) & (US$ Million)
Figure 59. Global Sales Market Share of Antiretroviral Agent by Type (2018-2029)
Figure 60. Global Revenue Market Share of Antiretroviral Agent by Type (2018-2029)
Figure 61. Global Antiretroviral Agent Price (US$/Unit) by Type (2018-2029)
Figure 62. Global Sales Market Share of Antiretroviral Agent by Application (2018-2029)
Figure 63. Global Revenue Market Share of Antiretroviral Agent by Application (2018-2029)
Figure 64. Global Antiretroviral Agent Price (US$/Unit) by Application (2018-2029)
Figure 65. Antiretroviral Agent Value Chain
Figure 66. Antiretroviral Agent Production Process
Figure 67. Channels of Distribution (Direct Vs Distribution)
Figure 68. Distributors Profiles
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed
